PreTT

PreTT is a biotechnology company specializing in the development of pre-targeted therapeutic platforms designed to enhance the precision and safety of cancer treatments. The company's core technology involves a two-step delivery system where a non-radioactive targeting agent is first localized at the tumor site, followed by the administration of a high-affinity payload. This approach aims to minimize off-target effects and systemic toxicity associated with traditional antibody-drug conjugates and radioimmunotherapy. PreTT is currently advancing a pipeline of candidates targeting various solid tumors, with a focus on improving outcomes for patients with refractory cancers.